Newly Diagnosed Acute Myeloid Leukemia (AML) Clinical Trials

7 clinical trials for Newly Diagnosed Acute Myeloid Leukemia (AML) across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia — RECRUITING · PHASE2
• Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML — RECRUITING · PHASE2
• SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE1
• Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER-2 trial — TERMINATED · PHASE3
• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation — ACTIVE_NOT_RECRUITING · PHASE3
• Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search